MiMedx Group Inc (MDXG)vsModerna Inc (MRNA)
MDXG
MiMedx Group Inc
$3.95
+1.28%
HEALTHCARE · Cap: $646.49M
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 527% more annual revenue ($2.23B vs $355.17M). MDXG leads profitability with a 1.8% profit margin vs -141.4%. MDXG earns a higher WallStSmart Score of 43/100 (D).
MDXG
Hold43
out of 100
Grade: D
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+87.4%
Fair Value
$41.37
Current Price
$3.95
$37.42 discount
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 99.5% YoY
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Reasonable price relative to book value
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Smaller company, higher risk/reward
ROE of 2.9% — below average capital efficiency
1.8% margin — thin
Weak financial health signals
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MDXG
The strongest argument for MDXG centers on EPS Growth, Debt/Equity, Altman Z-Score.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : MDXG
The primary concerns for MDXG are Market Cap, Return on Equity, Profit Margin. A P/E of 110.8x leaves little room for execution misses. Thin 1.8% margins leave little buffer for downturns.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MDXG profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.
MDXG carries more volatility with a beta of 1.17 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
MDXG generates stronger free cash flow (-11M), providing more financial flexibility.
Bottom Line
MDXG scores higher overall (43/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MiMedx Group Inc
HEALTHCARE · BIOTECHNOLOGY · USA
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?